Core Insights - Commodore Capital has fully exited its position in Scholar Rock Holding Corporation, selling approximately 1.5 million shares in Q3, which represented a net position change of about $51 million [1][2][10] Company Overview - Scholar Rock Holding Corporation is a biotechnology company focused on developing therapeutics for serious diseases driven by protein growth factor signaling, with a pipeline that includes neuromuscular, oncology, and fibrotic indications [5][8] - As of the latest data, Scholar Rock's share price is $41.08, with a market capitalization of $4.2 billion and a net income of -$353.4 million over the trailing twelve months [4][8] Financial Performance - The company reported a significant increase in Q3 operating expenses, rising to $103.6 million from $64.8 million the previous year, leading to a quarterly net loss of $102.2 million [11] - Scholar Rock has $369.6 million in cash, providing a runway into 2027 to support its programs through key catalysts expected in 2026 [11] Regulatory and Market Position - Scholar Rock is preparing to resubmit its apitegromab biologics license application following a constructive FDA meeting on November 12, which indicated progress in remediation efforts [10] - The company is entering a critical phase with potential regulatory milestones that could significantly impact its market position and investor sentiment [9][12]